| Basics |
Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
|
| IPO Date: |
April 14, 2004 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$3.9B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.31 | 2.78%
|
| Avg Daily Range (30 D): |
$1.82 | 2.86%
|
| Avg Daily Range (90 D): |
$1.81 | 2.53%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.49M |
| Avg Daily Volume (30 D): |
1.9M |
| Avg Daily Volume (90 D): |
1.07M |
| Trade Size |
| Avg Trade Size (Sh.): |
97 |
| Avg Trade Size (Sh.) (30 D): |
65 |
| Avg Trade Size (Sh.) (90 D): |
51 |
| Institutional Trades |
| Total Inst.Trades: |
4,598 |
| Avg Inst. Trade: |
$2.89M |
| Avg Inst. Trade (30 D): |
$4.62M |
| Avg Inst. Trade (90 D): |
$5.29M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.09M |
| Avg Closing Trade (30 D): |
$13.62M |
| Avg Closing Trade (90 D): |
$11.27M |
| Avg Closing Volume: |
140.52K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$1
|
$.19
|
$.33
|
|
Diluted EPS
|
$.87
|
$.16
|
$.29
|
|
Revenue
|
$ 741.17M
|
$ 207.64M
|
$ 194.43M
|
|
Gross Profit
|
$ 727.78M
|
$ 203.04M
|
$ 191M
|
|
Net Income / Loss
|
$ 106.11M
|
$ 19.67M
|
$ 35.15M
|
|
Operating Income / Loss
|
$ 65.57M
|
$ 10.22M
|
$ 26.68M
|
|
Cost of Revenue
|
$ 13.39M
|
$ 4.6M
|
$ 3.43M
|
|
Net Cash Flow
|
$ -12.15M
|
$ 22.39M
|
$ 12.93M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
